ALT · Altimmune, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $41.0K | $20.0K | $426.0K | $4.41M | $4.41M | $8.19M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $66.43M | $82.23M | $65.80M | $70.54M | $74.54M | $49.77M |
| SG&A | $28.10M | $20.97M | $18.14M | $17.13M | $15.41M | $13.21M |
| Total Operating Expenses | $94.53M | $103.19M | $96.36M | $87.67M | $101.32M | $62.98M |
| D&A | $112.0K | $238.0K | $477.0K | $500.0K | $551.3K | $298.1K |
| Operating Income | ($94.49M) | ($103.17M) | ($95.93M) | ($87.74M) | ($96.91M) | ($54.80M) |
| Interest Expense | $1.64M | $9.0K | $35.0K | $8.0K | $5.7K | $9.4K |
| Income Tax | ($681.0K) | - | - | ($197.0K) | - | ($5.42M) |
| Net Income | ($88.09M) | ($95.06M) | ($88.45M) | ($84.71M) | ($97.09M) | ($49.04M) |
| EPS - Basic | ($1.00) | ($1.34) | ($1.66) | ($1.81) | ($1.91) | - |
| EPS - Diluted | ($1.00) | ($1.34) | ($1.66) | ($1.81) | ($1.91) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $43.76M | $36.93M | $135.12M | $111.10M | $190.30M | $115.92M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.72M | $211.0K | $2.07M | $4.80M | $2.03M | $612.3K |
| Current Assets | $278.19M | $137.25M | $209.63M | $192.81M | $204.13M | $230.26M |
| Total Assets | $279.93M | $139.31M | $210.64M | $206.93M | $218.86M | $245.12M |
| Current Liabilities | $15.00M | $10.47M | $12.14M | $17.05M | $18.28M | $12.02M |
| Long-term Debt | $34.29M | - | - | $4.58M | $1.45M | $1.83M |
| Total Liabilities | $55.04M | $15.80M | $16.54M | $21.64M | $19.73M | $19.24M |
| Stockholders' Equity | $224.89M | $123.51M | $194.10M | $185.29M | $199.13M | $225.88M |
| Retained Earnings | ($649.48M) | ($561.39M) | ($466.33M) | ($377.88M) | ($293.17M) | ($186.42M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($67.53M) | ($79.85M) | ($75.81M) | ($62.59M) | ($78.24M) | ($34.44M) |
| Investing Cash Flow | ($132.47M) | ($28.39M) | $13.73M | ($73.40M) | $87.52M | ($72.09M) |
| Financing Cash Flow | $206.84M | $10.04M | $86.11M | $56.78M | $65.10M | $213.49M |
| CapEx | $11.0K | - | $47.0K | $126.0K | $12.12M | $204.0K |
| Free Cash Flow | ($67.55M) | - | ($75.86M) | ($62.71M) | ($90.36M) | ($34.64M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -230461.0% | -515860.0% | -22518.5% | -1989.6% | -2197.4% | -669.5% |
| EBITDA margin | -230187.8% | -514670.0% | -22406.6% | -1978.2% | -2184.9% | -665.9% |
| Net margin | -214861.0% | -475295.0% | -20762.2% | -1920.9% | -2201.4% | -599.2% |
| Free cash flow margin | -164746.3% | - | -17806.8% | -1422.0% | -2048.7% | -423.2% |
| FCF / Net income | 0.77 | - | 0.86 | 0.74 | 0.93 | 0.71 |
| R&D / Revenue | 162029.3% | 411130.0% | 15445.8% | 1599.5% | 1690.1% | 608.1% |
| SG&A / Revenue | 68531.7% | 104830.0% | 4257.5% | 388.5% | 349.5% | 161.4% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -31.5% | -68.2% | -42.0% | -40.9% | -44.4% | -20.0% |
| Return on equity | -39.2% | -77.0% | -45.6% | -45.7% | -48.8% | -21.7% |
| Return on invested capital | -28.8% | - | - | -36.5% | - | -19.0% |
| Liquidity | ||||||
| Current ratio | 18.55 | 13.11 | 17.26 | 11.31 | 11.17 | 19.16 |
| Quick ratio | 18.55 | 13.11 | 17.26 | 11.31 | 11.17 | 19.16 |
| Cash ratio | 2.92 | 3.53 | 11.13 | 6.51 | 10.41 | 9.64 |
| Leverage | ||||||
| Debt / Equity | 0.15 | - | - | 0.02 | 0.01 | 0.01 |
| Debt / Assets | 0.12 | - | - | 0.02 | 0.01 | 0.01 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -57.8x | -11463.6x | -2740.8x | -10967.5x | -17134.7x | -5816.7x |
| Equity multiplier | 1.24 | 1.13 | 1.09 | 1.12 | 1.10 | 1.09 |
| Liabilities / Assets | 0.20 | 0.11 | 0.08 | 0.10 | 0.09 | 0.08 |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.4x | 4.1x | 3.1x | 4.2x | 1.2x | - |
| P / S | 7757.5x | 25596.7x | 1406.2x | 175.0x | 53.2x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 105.0% | -95.3% | -90.3% | -0.0% | -46.1% | 41.1% |
| Revenue CAGR (3y) | -79.0% | -83.4% | -62.7% | -8.7% | -25.7% | 36.2% |
| Revenue CAGR (5y) | -65.3% | -67.8% | -47.6% | 6.4% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 8.4% | -7.6% | -9.3% | 9.5% | -76.9% | -155.3% |
| Net income growth (YoY) | 7.3% | -7.5% | -4.4% | 12.7% | -98.0% | -139.0% |
| EPS growth (YoY) | 25.4% | 19.3% | 8.3% | 5.2% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -21.0% | 30.6% | -160.8% | -260.7% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 82.1% | -36.4% | 4.8% | -7.0% | -11.8% | 396.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$500.0K totalGrant$500.0K · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-0.62
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Altimmune against the 5 most active filers in the same SIC group.